[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 138, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 59, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 48, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Executive Director & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao Ph.D.", "age": 64, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 50, "title": "Senior Vice President of Bioinformatics & Information Technology", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 58, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 54, "title": "Senior Vice President of Early Drug Discovery", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 38, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jiping  Zha M.D., Ph.D.", "title": "Executive Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Songmao  Zheng Ph.D.", "title": "Senior VP of Clinical Pharmacology & Quantitative Sciences", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.89, "open": 1.82, "dayLow": 1.78, "dayHigh": 1.8694, "regularMarketPreviousClose": 1.89, "regularMarketOpen": 1.82, "regularMarketDayLow": 1.78, "regularMarketDayHigh": 1.8694, "payoutRatio": 0.0, "beta": 0.714, "forwardPE": -2.5555556, "volume": 5116, "regularMarketVolume": 5116, "averageVolume": 130080, "averageVolume10days": 29860, "averageDailyVolume10Day": 29860, "bid": 1.86, "ask": 1.99, "bidSize": 1, "askSize": 1, "marketCap": 86721544, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 3.16, "allTimeHigh": 31.83, "allTimeLow": 0.9, "priceToSalesTrailing12Months": 840.2925, "fiftyDayAverage": 1.82674, "twoHundredDayAverage": 1.863095, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 52423696, "profitMargins": 0.0, "floatShares": 29785784, "sharesOutstanding": 47131270, "sharesShort": 15970, "sharesShortPriorMonth": 40692, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.00029999999, "heldPercentInsiders": 0.047, "heldPercentInstitutions": 0.34219003, "shortRatio": 0.07, "shortPercentOfFloat": 0.0004, "impliedSharesOutstanding": 47131270, "bookValue": 0.804, "priceToBook": 2.2885573, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -29889636, "trailingEps": -0.64, "forwardEps": -0.72, "enterpriseToRevenue": 507.962, "enterpriseToEbitda": -1.6, "52WeekChange": -0.04545456, "SandP52WeekChange": 0.14561749, "quoteType": "EQUITY", "currentPrice": 1.84, "targetHighPrice": 21.07, "targetLowPrice": 3.5, "targetMeanPrice": 9.22429, "targetMedianPrice": 8.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 62828156, "totalCashPerShare": 1.066, "ebitda": -32765248, "totalDebt": 6849932, "quickRatio": 2.203, "currentRatio": 2.292, "totalRevenue": 103204, "debtToEquity": 18.068, "revenuePerShare": 0.002, "returnOnAssets": -0.24893999, "returnOnEquity": -0.63259, "grossProfits": 103204, "freeCashflow": -17171550, "operatingCashflow": -27456540, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -322.83603, "financialCurrency": "USD", "symbol": "ADAG", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -2.6455002, "regularMarketPrice": 1.84, "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "exchange": "NGM", "messageBoardId": "finmb_118162960", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.84, "postMarketChange": 0.0, "regularMarketChange": -0.049999952, "regularMarketDayRange": "1.78 - 1.8694", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 130080, "fiftyTwoWeekLowChange": 0.5400001, "fiftyTwoWeekLowChangePercent": 0.41538468, "fiftyTwoWeekRange": "1.3 - 3.16", "fiftyTwoWeekHighChange": -1.32, "fiftyTwoWeekHighChangePercent": -0.4177215, "fiftyTwoWeekChangePercent": -4.545456, "earningsTimestampStart": 1753268340, "earningsTimestampEnd": 1753704000, "isEarningsDateEstimate": true, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1767388204, "regularMarketTime": 1767387600, "epsTrailingTwelveMonths": -0.64, "epsForward": -0.72, "epsCurrentYear": -0.65, "priceEpsCurrentYear": -2.8307693, "fiftyDayAverageChange": 0.013260007, "fiftyDayAverageChangePercent": 0.007258836, "twoHundredDayAverageChange": -0.023095012, "twoHundredDayAverageChangePercent": -0.012396046, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-09", "cryptoTradeable": false, "displayName": "Adagene", "trailingPegRatio": null, "__fetch_time": "2026-01-03"}]